Article
Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
BMC musculoskeletal disorders - 29 May 2015
Ally Mahmood M T M, Hodkinson Bridget, Meyer Pieter W A, Musenge Eustasius, Tintinger Gregory R, Tikly Mohammed, Anderson Ronald
Abstract excerpt
BACKGROUND: To measure circulating anti-citrullinated peptide antibodies (ACPA) and cytokines pre- and 6 months post-therapy as a strategy to predict and optimize responses to traditional disease-modifying antirheumatic drugs (DMARDs) in early RA, which is an unmet need in developing countries. PATIENTS AND METHODS: A cohort of 140 predominantly (88.5 %) black female South African patients with early RA was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.